Influence of menstrual cycle on platelet serotonin uptake site and serotonin2A receptor binding.
Depression and anxiety are common health problems affecting women, particularly during the reproductive years. Major depression is two to three times as common in women than in men. Neuroendocrine factors are likely to contribute to this overall increased risk for developing mood disorders in women, and the neuroendocrine influence is most obviously seen in women with premenstrual dysphoric disorder (PMDD) as these women experience depressed mood and anxiety premenstrually only during ovulatory cycles. Moreover, dysfunction of serotonergic transmission has been regarded as an important mechanism in several psychiatric disorders and ovarian steroids have been shown to profoundly influence the activity of the serotonergic system. Given these facts, the purpose of this study was to examine whether binding of [3H]paroxetine to the platelet serotonin transporter or binding of [3H]lysergic acid diethylamide ([3H]LSD) to the platelet 5-HT2A receptor are influenced by the cyclical changes in circulating estradiol and progesterone that occur during the menstrual cycle. We examined 28 healthy women, without oral contraceptives and with regular menstrual cycles. In the late follicular phase, Bmax for [3H]paroxetine binding was significantly higher than in the ovulatory (p<0.01), early luteal phase (p<0.05) and mid-luteal phase (p<0.01). Bmax for [3H]LSD binding was significantly higher in the early follicular phase and the early luteal phase compared to the mid-luteal phase (p<0.001 and p<0.05, respectively). In the early follicular phase and the ovulatory phase, significant correlations between estradiol serum concentrations and Kd for [3H]paroxetine were obtained (p<0.001, respectively). In the luteal phase, significant inverse correlations between progesterone as well as estradiol serum concentrations and Kd for [3H]LSD binding were found (p<0.05, respectively).
Wihlbäck
Anna-Carin
AC
Department of Clinical Sciences/Obstetrics and Gynecology, University Hospital of Umeå, S-901 85 Umea, Sweden. anna-carin.wihlback@obgyn.umu.se
Sundström Poromaa
Inger
I
Bixo
Marie
M
Allard
Per
P
Mjörndal
Tom
T
Spigset
Olav
O
D000328:Adult; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism*; D002352:Carrier Proteins / Q000187:drug effects / Q000378:metabolism*; D004958:Estradiol / Q000097:blood; D005260:Female; D006801:Humans; D008238:Lysergic Acid Diethylamide / Q000378:metabolism; D008597:Menstrual Cycle / Q000378:metabolism*; D017374:Paroxetine / Q000378:metabolism; D011374:Progesterone / Q000097:blood; D044402:Receptor, Serotonin, 5-HT2A / Q000187:drug effects / Q000378:metabolism*; D012016:Reference Values; D012701:Serotonin / Q000378:metabolism*; D050486:Serotonin Plasma Membrane Transport Proteins; D017366:Serotonin Receptor Agonists / Q000378:metabolism; D017367:Selective Serotonin Reuptake Inhibitors / Q000378:metabolism
D002352:Carrier Proteins; D004958:Estradiol; D008238:Lysergic Acid Diethylamide; D017374:Paroxetine; D011374:Progesterone; D044402:Receptor, Serotonin, 5-HT2A; D012701:Serotonin; D050486:Serotonin Plasma Membrane Transport Proteins; D017366:Serotonin Receptor Agonists; D017367:Selective Serotonin Reuptake Inhibitors